Provided by Tiger Fintech (Singapore) Pte. Ltd.

Royalty Pharma plc

36.73
+0.32080.88%
Volume:316.76K
Turnover:11.56M
Market Cap:21.42B
PE:15.80
High:36.75
Open:36.24
Low:36.23
Close:36.41
52wk High:38.00
52wk Low:24.05
Shares:583.17M
Float Shares:379.85M
Volume Ratio:0.42
T/O Rate:0.08%
Dividend:0.86
Dividend Rate:2.34%
EPS(TTM):2.32
EPS(LYR):1.92
ROE:17.29%
ROA:6.49%
PB:3.37
PE(LYR):19.16

Loading ...

Company Profile

Company Name:
Royalty Pharma plc
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
- -
Office Location:
110 East 59th Street,New York,New York,United States
Zip Code:
10022
Fax:
- -
Introduction:
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Directors

Name
Position
Christopher Hite
Executive Vice President and Vice Chairman
Pablo Legorreta
Chairman of the Board and Chief Executive Officer
Bonnie Bassler
Independent Director
Catherine Engelbert
Independent Director
David Hodgson
Independent Director
Errol De Souza
Independent Director
Greg Norden
Independent Director
M. Germano Giuliani
Independent Director
Rory Riggs
Independent Director
Ted Love
Independent Director
Vlad Coric
Independent Director
Carole Ho
Director
Elizabeth Weatherman
Director

Shareholders

Name
Position
Pablo Legorreta
Chairman of the Board and Chief Executive Officer
Terrance Coyne
Principal Accounting Officer, Executive Vice President and Chief Financial Officer
Christopher Hite
Executive Vice President and Vice Chairman
George Lloyd
Executive Vice President, Investments and Chief Legal Officer
Marshall Urist
Executive Vice President, Research and Investments